KOSDAQBiotech & Pharma338220

Vuno

₩5,270▼ 0.19%2026-11-18 close
Market Cap
₩73.8B
Turnover
₩300M
Volume
60K
Shares out.
14M
PER
—
PBR
3.1×
EPS
-₩1,003
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

DeepCARS Review Is Vuno's Next Test

Vuno's DeepCARS accounts for about 87% of 2026 year-to-date revenue, and the company has posted losses for four straight quarters, so the outcome of the health technology assessment and overseas approvals are the next checkpoints.

  1. 1

    On a disclosed basis, 2025 annual revenue was KRW 34.8 billion, up 34.7% year on year, and the operating loss narrowed to KRW 4.93 billion.

  2. 2

    Revenue in the third quarter of 2026 was KRW 5.67 billion, down 47.6% from a year earlier, and the operating loss was KRW 1.97 billion.

  3. 3

    According to the company, DeepCARS revenue in the third quarter of 2026 was about KRW 5 billion, down roughly 28% year on year, with slower new hospital adoption cited as the cause.

  4. 4

    The company expects a DeepCARS assessment result in the fourth quarter of 2026, and whether reimbursement follows is seen as the first gate for a revenue recovery.

  5. 5

    Overseas, Vuno is advancing contract and validation-stage projects, including a two-year exclusive sales deal in Hainan, China, a licensing target in Kuwait, and completed EMR integration in Germany.

02

Business structure

Vuno is a medical AI company centered on biosignal-based solutions. In 2025 it divested non-core businesses, transferring the BoneAge bone-age analysis business to MyHub for KRW 2.7 billion, after earlier selling its chest CT solution to Corelinesoft for KRW 3.4 billion.

The core revenue driver is VUNO Med-DeepCARS, which predicts cardiac arrest risk in hospitalized patients. According to the company, DeepCARS generated KRW 15.5 billion of the KRW 17.8 billion cumulative revenue for January to September 2026, or about 87%.

The second line is HATIV, a portable ECG device, whose cumulative revenue for the same period was KRW 1.6 billion, up 18% year on year and about 9% of the total. HATIV growth has come from kiosk-type K30 units deployed for occupational safety at sites such as construction areas outside hospitals.

DeepCARS takes data such as blood pressure, heart rate, respiratory rate and temperature from electronic medical records and produces a 0 to 100 risk score for the next 24 hours, with hospitals as the main customers.

Imaging-assist products include the Fundus AI retinal tool, which has a sales contract in Germany, and the Chest X-ray tool, which is in proof-of-concept testing in Southeast Asia.

Industry commentary notes that major domestic medical AI companies have grown revenue since founding but have not yet reached profitability.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩10.8B₩1B9.4%
2025Q4₩7.2B-₩2.4B−32.5%
2026Q1₩6B-₩4.1B−67.9%
2026Q2₩6.1B-₩4.2B−68.9%
2026Q3₩5.7B-₩2B−34.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.3B-₩15.4B-₩15.7B−185.7%−83.8%89.3%
2023₩13.3B-₩15.7B-₩15.6B−118.1%−311.3%349.4%
2024₩25.9B-₩12.5B-₩13B−48.1%−42.4%63.5%
2025₩34.8B-₩4.9B-₩5.8B−14.2%−16.0%39.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Disclosed annual revenue was KRW 8.27 billion in 2022, KRW 13.3 billion in 2023 (up 60.4%), KRW 25.9 billion in 2024 (up 94.9%) and KRW 34.8 billion in 2025 (up 34.7%). Revenue rose for three consecutive years from 2023 to 2025, and 2025 was the largest year of 2022 to 2025. Growth rates slowed after the 2024 peak.

Operating losses over the same period were KRW 15.4 billion in 2022, KRW 15.7 billion in 2023 (losses widened), KRW 12.5 billion in 2024 (losses narrowed) and KRW 4.93 billion in 2025 (losses narrowed), a loss in each of the four years from 2022 to 2025.

The operating margin improved from -185.7% in 2022 to -14.2% in 2025. The net loss attributable to controlling shareholders fell from KRW 15.7 billion in 2022 to KRW 5.78 billion in 2025, and the net loss including non-controlling interests followed the same path.

At the end of 2025, total equity was KRW 36.1 billion and total liabilities were KRW 14.3 billion, with the debt ratio falling from 349.4% in 2023 to 39.5% in 2025. Operating cash flow improved from negative KRW 16.3 billion in 2022 to negative KRW 4.68 billion in 2025.

Quarterly revenue peaked at KRW 10.8 billion in the third quarter of 2025, when operating profit was KRW 1.02 billion, and then fell to KRW 7.23 billion in the fourth quarter of 2025 (operating loss of KRW 2.35 billion, a swing to loss), KRW 6.05 billion in the first quarter of 2026 (operating loss of KRW 4.11 billion), KRW 6.11 billion in the second quarter (operating loss of KRW 4.21 billion) and KRW 5.67 billion in the third quarter (operating loss of KRW 1.97 billion).

Quarterly filings showed about KRW 3.04 billion of other income from a solution transfer in the third quarter of 2025, and about 59% of the KRW 5.15 billion revenue decline in the third quarter of 2026 was attributed to the absence of that income. Operating expenses in the same quarter fell 22.1% to KRW 7.64 billion.

05

Industry analysis

Medical AI in Korea faces a long gap between product approval and reimbursement, so companies keep spending on R&D and overseas expansion. DeepCARS was confirmed in May 2022 as the first domestic medical AI product under the fast-track pathway and entered the non-reimbursed market that August.

After the health technology assessment grace period ended in March 2026, the full assessment is under way, and hospitals may still use the product on a non-reimbursed basis during review.

A separate reimbursement decision follows if the product passes, and the company says a finding of research-stage status would restrict on-site use. Revenue therefore still depends on existing hospital customers.

Overseas, DeepCARS received CE-MDR certification in Europe in 2025, and in Hainan, China, the company is using a pilot-zone system to build local evidence. The Fundus AI tool has been connected to a chronic disease management platform in Jiangsu Province and is in use at public medical institutions there.

In the Middle East, a Kuwaiti national hospital is running a proof-of-concept study with a target of local approval within 2026.

Many domestic medical AI companies remain loss-making, and Vuno's distinguishing point is a product that generates hospital revenue, while the concentration of sales in a single product is cited as the main weakness.

06

Outlook

The company expects headcount reductions and other cost efficiency measures to be fully reflected in earnings from 2027. Operating expenses in the third quarter of 2026 were KRW 7.64 billion, down 26% from the prior quarter.

The company expects a DeepCARS health technology assessment result in the fourth quarter of 2026, and it says reimbursement would reduce patient cost-sharing and remove the separate consent step, which it expects to raise usage in hospitals.

Overseas, Vuno signed a two-year exclusive sales agreement with China's Guorun for Hainan Province in September 2026, and it has set a target of completing local hospital registration within six months of that announcement.

In Europe, research collaborations with hospitals in Germany, Spain and Sweden are under way, and the system integration with the German EMR company Mesalvo is complete. In the Middle East, a proof-of-concept study at a Kuwaiti national hospital targets local approval within 2026.

HATIV reportedly signed its first export contract in the Middle East in the second quarter of 2026. Fundus AI completed local validation in Germany and signed a sales contract with a medical device distributor there, while approval and hospital validation are running in parallel in Brazil.

The Chest X-ray tool is in technical validation at hospitals in Vietnam and Thailand, and the company says a sales contract is near.

07

Valuation

PER
—
PBR
3.1×
ROE
-54.3%
EPS
-₩1,003
BPS
₩1,718
Dividend per share
₩0

The price-to-book ratio is well above 1x, meaning the shares trade at a clear premium to book value.

Total equity at the end of 2025 was KRW 36.1 billion, so the asset base remains intact despite losses, but the premium depends more on whether the DeepCARS assessment and overseas contracts convert into earnings than on current book value.

Because the last four quarters have produced a combined net loss attributable to controlling shareholders of KRW 14 billion, earnings-based multiples cannot be calculated. The company posted a quarterly profit in the third quarter of 2025 but has reported losses in each quarter since.

The dividend yield is effectively nil, so dividend-based comparisons are not meaningful. Among domestic medical AI companies many remain loss-making, which limits the usefulness of earnings-based peer multiples.

Over several years, operating losses and the operating margin have narrowed since 2022, a shift from widening to narrowing losses. The next reference points for valuation are the DeepCARS assessment outcome, the timing of overseas revenue, and whether cost cuts show up in reported results.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Reimbursement Possibility if DeepCARS Passes

The company expects the DeepCARS assessment result in the fourth quarter of 2026. If the product passes and gains insurance coverage, the company says patient cost-sharing would fall and hospital usage could rise.

The product already has an installed base in about 50,000 hospital beds in Korea on a non-reimbursed basis. Reimbursement could reverse the slowdown in new adoption.

Overseas Approvals and Contract Pipeline

Vuno signed a two-year exclusive sales deal with Guorun for Hainan in September 2026 and is running a proof-of-concept study in Kuwait with a 2026 approval target. Research collaborations with hospitals in Germany, Spain and Sweden continue.

Fundus AI has a sales contract in Germany, and HATIV signed a first export contract in the Middle East. If these contracts translate into revenue, they would broaden the revenue base beyond DeepCARS.

Cost Efficiency and Narrowing Losses

The operating loss narrowed to KRW 1.97 billion in the third quarter of 2026 from KRW 4.21 billion in the second quarter, and operating expenses fell 26% from the prior quarter. The company expects headcount reductions and other efficiency measures to be reflected from 2027.

The operating margin improved from -185.7% in 2022 to -14.2% in 2025. Even with continued losses, the narrowing trend is a point supporters cite.

09

Bear factors

Slower New Adoption and Revenue Decline

Revenue in the third quarter of 2026 was KRW 5.67 billion, down 47.6% from a year earlier. The company says DeepCARS revenue alone was about KRW 5 billion in the quarter, down roughly 28%, with slower new adoption as the reason.

The prior-year quarter included solution transfer income, which creates a base effect, but the core product's revenue trend is not clearly growing.

Four Straight Quarterly Losses and Funding Pressure

The company has posted losses for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026, with a combined net loss attributable to controlling shareholders of KRW 14 billion over that span. Operating cash flow was still negative at KRW 4.68 billion in 2025.

Total equity at the end of 2025 was KRW 36.1 billion, but continued losses could require additional funding, and the form of that funding could dilute existing shareholders.

Overseas Business Still at Contract and Validation Stage

Sales of DeepCARS in Hainan require local hospital registration before proof-of-concept work, with a six-month registration target. The Kuwait approval is still a target. Germany, the Middle East and Southeast Asia are mostly at research, pilot or validation stages, and disclosed overseas revenue remains limited. If overseas expansion slips, it would be hard to offset the domestic slowdown.

10

Risk factors

Regulatory and Assessment Risk

DeepCARS exited its assessment grace period in March 2026 and is under full health technology assessment. The company expects a result in the fourth quarter, but a finding of research-stage status would restrict on-site use.

The timing and content of the outcome are outside the company's control, and a separate reimbursement decision remains after that.

Single-Product Concentration

DeepCARS accounts for about 87% of revenue for January through September 2026, and HATIV for about 9%. Any slowdown in hospital adoption or policy change for DeepCARS flows directly into company results.

HATIV is growing faster but is still small relative to the total, so concentration risk remains until diversification shows up in revenue.

Financial Capacity and Cost Execution

Total liabilities at the end of 2025 were KRW 14.3 billion, and the debt ratio fell to 39.5% from 349.4% in 2023, but operating cash flow remained negative. The efficiency gains the company describes depend on headcount reductions and cost execution proceeding as planned from 2027. If spending rises again while pursuing overseas expansion and R&D, the narrowing of losses could reverse.

11

What to watch next

  1. Q4 2026

    Result of the DeepCARS health technology assessment. The outcome determines the next reimbursement step and the outlook for hospital usage, making it the first item to check.

  2. End of 2026

    Whether local approval in Kuwait is obtained as the proof-of-concept concludes. Approval within the target window would indicate the pace of Middle East execution.

  3. Around March 2027

    Completion of local hospital registration in Hainan. The company set a six-month target in its September 2026 announcement, which runs into roughly March 2027.

  4. End of March 2027 (annual report deadline)

    Filing of the 2026 annual report, the next regular filing. It will show full-year 2026 operating loss, cash flow and capital structure on a disclosed basis.

12

Overall view

Vuno depends heavily on one product, DeepCARS, which generated about 87% of revenue for January through September 2026. Annual revenue rose to KRW 34.8 billion in 2025, a third straight annual increase, but third-quarter 2026 revenue fell 47.6% from a year earlier.

The operating loss has been recorded in each year from 2022 to 2025, though it narrowed in 2024 and 2025, and the third-quarter 2026 operating loss of KRW 1.97 billion was smaller than in the prior quarter.

Supporting factors include possible reimbursement if DeepCARS passes assessment, expanding overseas contracts in China and the Middle East, and cost efficiency.

Opposing factors include slower new adoption, four straight quarterly losses that add funding pressure, and overseas business that remains at contract and validation stages. The price-to-book ratio sits well above 1x, and earnings-based multiples cannot be calculated.

The next checkpoints are the DeepCARS assessment result in the fourth quarter of 2026, the Kuwait approval target at year-end, and the 2026 annual report due by the end of March 2027. Whether the assessment result and overseas revenue materialize will be the key variables for the earnings trajectory.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.nate.com
  2. vuno.co
  3. denews.co.kr
  4. thebionews.net
  5. getnews.co.kr
  6. rapportian.com
  7. paxetv.com
  8. finance.eduinfom.com
  9. m.news.nate.com
  10. newstap.co.kr
  11. news.mtn.co.kr
  12. vuno.co
  13. thebionews.net
  14. etoday.co.kr
  15. vuno.co
  16. alphabiz.co.kr
  17. fnnews.com
  18. ddaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis